Assembly Biosciences (ASMB)

$18.75 +0.53 (2.91%)
Market Cap 143.21M
Revenue (ttm) 28.52M
Net Income (ttm) -40.18M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -140.88%
Debt to Equity Ratio 0.00
Volume 30,200
Avg Vol 29,316
Day's Range N/A - N/A
Shares Out 7.64M
Stochastic %K 78%
Beta 0.62
Analysts Strong Sell
Price Target $31.67

Company Profile

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5336 and ABI-1179, which are in Phase 1a/1b clinical studies for recurrent genital herpes; ABI-4334, a capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus that is in Phase 1b clinical study; and ABI-6250, an orally bioavailable hepatitis delta...

Industry: Biotechnology
Sector: Healthcare
Phone: 833 509 4583
Address:
Two Tower Place, 7th Floor, South San Francisco, United States
BioMan122
BioMan122 Jul. 13 at 3:45 PM
$ASMB i expect next leg up very soon…
0 · Reply
onemillion2012
onemillion2012 Jul. 12 at 8:14 AM
$ASMB $GILD
1 · Reply
Dachshundtrader
Dachshundtrader Jul. 11 at 4:54 PM
🚨 $ASMB with only ~7.6M shares outstanding and a float even lower – Tight float + zero retail = powder keg setup. With 3 clinical readouts coming + $GILD opt-in optionality, any real volume could send this vertical. Low float biotech plays don’t get cleaner than this.
0 · Reply
FelixH86
FelixH86 Jul. 11 at 3:59 PM
$ASMB nice weekend..
0 · Reply
onemillion2012
onemillion2012 Jul. 10 at 2:34 PM
$RXST sold. 20 percent gain on one day beautiful. Do i buy $ASMB or $VNDA
4 · Reply
Loesemeff
Loesemeff Jul. 9 at 9:33 PM
$ASMB
0 · Reply
Dachshundtrader
Dachshundtrader Jul. 9 at 6:40 PM
📈 $ASMB shaping up as one of the most asymmetric biotech setups out there: ✔️ $GILD opt-in clock ticking (HBV) ✔️ HDV & HSV data readouts lined up for Q3/Q4 ✔️ $90M cash, < $140M mcap, zero hype All the ingredients are there....
0 · Reply
FelixH86
FelixH86 Jul. 9 at 4:49 PM
$ASMB
0 · Reply
BioMan122
BioMan122 Jul. 9 at 2:47 PM
$ASMB this stock is so sleepy. but once it awakes it will be powerful…
1 · Reply
FelixH86
FelixH86 Jul. 7 at 2:49 PM
$ASMB wow - good start in the week..19 would be nice
0 · Reply
Latest News on ASMB
Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

Jun 30, 2025, 8:00 AM EDT - 13 days ago

Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

Jun 25, 2025, 8:00 AM EDT - 18 days ago

Assembly Biosciences Reports Positive Topline Results from Phase 1b Clinical Trial of Next-Generation Investigational Capsid Assembly Modulator ABI-4334 in Chronic Hepatitis B

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

May 27, 2025, 4:05 PM EDT - 6 weeks ago

Assembly Biosciences to Present During the Jefferies 2025 Global Healthcare Conference

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

May 8, 2025, 4:05 PM EDT - 2 months ago

Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates

New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

May 7, 2025, 8:00 AM EDT - 2 months ago

New Preclinical Data for Assembly Biosciences' Oral Hepatitis D Virus Entry Inhibitor ABI-6250 and Next-Generation Hepatitis B Virus Capsid Assembly Modulator ABI-4334 Presented at the EASL Congress 2025

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Apr 9, 2025, 2:00 AM EDT - 3 months ago

Assembly Biosciences Presents New Data Highlighting Long-Acting Herpes Simplex Virus Candidate ABI-5366 and Genital Herpes Prevalence and Treatment Patterns at the 2025 ESCMID Congress

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Mar 20, 2025, 4:05 PM EDT - 4 months ago

Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Feb 26, 2025, 8:00 AM EST - 4 months ago

Assembly Biosciences Doses First Participant in Phase 1a Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Feb 20, 2025, 8:00 AM EST - 5 months ago

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Dec 26, 2024, 8:00 AM EST - 7 months ago

Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Jul 15, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

May 22, 2024, 8:00 AM EDT - 1 year ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress™ 2024

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

May 8, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Mar 28, 2024, 4:05 PM EDT - 1 year ago

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Assembly Biosciences Announces Effective Date of Reverse Stock Split

Feb 8, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Announces Effective Date of Reverse Stock Split

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Jan 4, 2024, 8:00 AM EST - 1 year ago

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 10, 2023, 4:05 PM EST - 1 year ago

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Nov 8, 2023, 8:00 AM EST - 1 year ago

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

Oct 17, 2023, 7:00 AM EDT - 1 year ago

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

GILD

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

Oct 11, 2023, 8:00 AM EDT - 1 year ago

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

Oct 2, 2023, 8:00 AM EDT - 1 year ago

Assembly Biosciences Nominates Development Candidate ABI-6250, an Orally Bioavailable HDV Entry Inhibitor

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

Sep 19, 2023, 4:05 PM EDT - 1 year ago

Assembly Biosciences to Highlight Pipeline Progress in HBV and HDV at the 2023 International HBV Meeting

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

Jul 17, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences Presents New Data Highlighting Herpes Simplex Virus Development Candidate ABI-5366 at the 47th Annual International Herpesvirus Workshop

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL International Liver Congress™ 2023

Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference

May 23, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences to Present During the 2023 Jefferies Healthcare Conference

Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

May 4, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences Reports First Quarter 2023 Financial Results and Recent Highlights

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Mar 22, 2023, 4:05 PM EDT - 2 years ago

Assembly Biosciences Provides Update on its Core Inhibitor Pipeline, Reports Fourth Quarter and Year End 2022 Financial Results and Recent Highlights

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Jan 17, 2023, 7:00 AM EST - 2 years ago

Carver Biosciences Announces Appointment of Three Members to its Scientific Advisory Board

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Nov 4, 2022, 8:00 AM EDT - 2 years ago

Assembly Biosciences Presents New Data at AASLD The Liver Meeting® Highlighting Breadth of Virology Portfolio and Potential of Next-Generation Core Inhibitors in HBV

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®

Oct 24, 2022, 8:00 AM EDT - 2 years ago

Assembly Biosciences to Present Data in Four Poster Presentations at Upcoming AASLD The Liver Meeting®

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A.

Oct 5, 2022, 4:05 PM EDT - 3 years ago

Assembly Bio Announces Retirement of John G. McHutchison, AO, MD as CEO and Appoints Current President and COO Jason A.

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Aug 9, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Reports Second Quarter 2022 Financial Results and Recent Highlights

Assembly Biosciences Announces Program Reprioritization and Organizational Update

Jul 20, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Announces Program Reprioritization and Organizational Update

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Jun 22, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Presents New Data Highlighting Clinical Progress of Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022

Jun 21, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Introduce New Small Molecule Liver-Focused Interferon-α Receptor Agonist Research Program in Webcast on July 26, 2022

Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Jun 8, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences to Highlight Data from HBV Core Inhibitor Programs at EASL's International Liver Congress™ 2022

Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

Jun 6, 2022, 8:00 AM EDT - 3 years ago

Assembly Biosciences Initiates Phase 1b Clinical Trial Evaluating Next Generation Core Inhibitor ABI-H3733 for the Treatment of Chronic Hepatitis B Virus Infection

Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

May 12, 2022, 4:05 PM EDT - 3 years ago

Assembly Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights

Mar 10, 2022, 4:05 PM EST - 3 years ago

Assembly Biosciences Reports Fourth Quarter and Year End 2021 Financial Results and Recent Highlights

Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference

Feb 9, 2022, 8:00 AM EST - 3 years ago

Assembly Biosciences to Present During the SVB Leerink 11th Annual Global Healthcare Conference

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 7, 2022, 5:00 PM EST - 3 years ago

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference

Jan 6, 2022, 8:00 AM EST - 3 years ago

Assembly Biosciences Announces Presentation During the 2022 H.C. Wainwright BIOCONNECT Virtual Conference

Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibitor Portfolio

Nov 12, 2021, 8:00 AM EST - 3 years ago

Assembly Biosciences Presents New Data at AASLD The Liver Meeting™ Highlighting the Progress of its HBV Core Inhibitor Portfolio

Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®

Nov 1, 2021, 10:32 AM EDT - 4 years ago

Assembly Biosciences Abstracts Selected for Presentation at the Upcoming AASLD The Liver Meeting®

Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

Oct 19, 2021, 7:30 AM EDT - 4 years ago

Antios Therapeutics and Assembly Biosciences Announce Clinical Collaboration Agreement to Evaluate the Combination of ATI-2173 and Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

Assembly Bio Announces October Conference Participation

Oct 6, 2021, 8:00 AM EDT - 4 years ago

Assembly Bio Announces October Conference Participation

Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158

Sep 1, 2021, 4:02 PM EDT - 4 years ago

Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158

Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

Aug 18, 2021, 8:00 AM EDT - 4 years ago

Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

Aug 5, 2021, 4:01 PM EDT - 4 years ago

Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

BioMan122
BioMan122 Jul. 13 at 3:45 PM
$ASMB i expect next leg up very soon…
0 · Reply
onemillion2012
onemillion2012 Jul. 12 at 8:14 AM
$ASMB $GILD
1 · Reply
Dachshundtrader
Dachshundtrader Jul. 11 at 4:54 PM
🚨 $ASMB with only ~7.6M shares outstanding and a float even lower – Tight float + zero retail = powder keg setup. With 3 clinical readouts coming + $GILD opt-in optionality, any real volume could send this vertical. Low float biotech plays don’t get cleaner than this.
0 · Reply
FelixH86
FelixH86 Jul. 11 at 3:59 PM
$ASMB nice weekend..
0 · Reply
onemillion2012
onemillion2012 Jul. 10 at 2:34 PM
$RXST sold. 20 percent gain on one day beautiful. Do i buy $ASMB or $VNDA
4 · Reply
Loesemeff
Loesemeff Jul. 9 at 9:33 PM
$ASMB
0 · Reply
Dachshundtrader
Dachshundtrader Jul. 9 at 6:40 PM
📈 $ASMB shaping up as one of the most asymmetric biotech setups out there: ✔️ $GILD opt-in clock ticking (HBV) ✔️ HDV & HSV data readouts lined up for Q3/Q4 ✔️ $90M cash, < $140M mcap, zero hype All the ingredients are there....
0 · Reply
FelixH86
FelixH86 Jul. 9 at 4:49 PM
$ASMB
0 · Reply
BioMan122
BioMan122 Jul. 9 at 2:47 PM
$ASMB this stock is so sleepy. but once it awakes it will be powerful…
1 · Reply
FelixH86
FelixH86 Jul. 7 at 2:49 PM
$ASMB wow - good start in the week..19 would be nice
0 · Reply
onemillion2012
onemillion2012 Jul. 7 at 12:20 PM
$ASMB let's break $20 this week. $NKTR $VNDA $ALT come my friends and join the party.
1 · Reply
FelixH86
FelixH86 Jul. 7 at 5:36 AM
$ASMB
0 · Reply
onemillion2012
onemillion2012 Jul. 4 at 12:14 PM
$ASMB my first buy. Was $69 when taking the RS in count. There is a long way to " in the money" and 5 years lost in profits
3 · Reply
FelixH86
FelixH86 Jul. 3 at 10:05 PM
$ASMB let' go...:-)
0 · Reply
FelixH86
FelixH86 Jul. 3 at 1:36 PM
$ASMB added 333...i am new...:-)
1 · Reply
boohoooomillenials
boohoooomillenials Jul. 2 at 2:28 PM
$ERAS strong buy signals . $ASMB $RUM showing almost 100% returns to come within a year. $DAIC huge run
0 · Reply
onemillion2012
onemillion2012 Jul. 2 at 2:19 PM
$VNDA it's a good stock. $ASMB $NKTR come and buy quality. With real revenue. More cash then marked cap. If the get approved there drugs we are seeing yearly sales +1Billion in 2029. Opportunity of a lifetime at this price.
0 · Reply
BioMan122
BioMan122 Jul. 1 at 1:42 PM
$ASMB some months ago gilead payed even more than $ 20 BEFORE recent great news
0 · Reply
BioMan122
BioMan122 Jul. 1 at 7:24 AM
$ASMB soon to the moon
0 · Reply
Haifischflosse
Haifischflosse Jul. 1 at 5:05 AM
$ASMB Now it's finally starting. The chart looks like a major breakout. The volume has increased dramatically. It will now rise until September, and then I hope that after good data, the takeover will come to at least $100.
0 · Reply
wonapenny
wonapenny Jun. 30 at 11:40 PM
$ASMB what was the price of ASMB when schornstein was really pushing it in NBC?
2 · Reply
Zonata
Zonata Jun. 30 at 5:20 PM
$ASMB I regret not buying back the shares I sold... we quietly more than doubled since the last dump. Fortunately, I still hold a lot. Overall this is still a losing position for me since I started a long time ago before the last failed clinical trial, but I'm hoping that trading this I'll get in the green.
1 · Reply